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http://arthritis-research.com/content/16/4/417RESEARCH ARTICLE Open AccessMonocyte-derived dendritic cells from HLA-B27+
axial spondyloarthritis (SpA) patients display
altered functional capacity and deregulated
gene expression
Alice Talpin1,2, Félicie Costantino1,2,3, Nelly Bonilla4, Ariane Leboime3, Franck Letourneur4, Sébastien Jacques4,
Florent Dumont4, Sonia Amraoui4,5, Charles-Antoine Dutertre6, Henri-Jean Garchon1,2,3,7, Maxime Breban1,2,3
and Gilles Chiocchia1,2*Abstract
Introduction: This study aimed to compare the functional capacity and gene expression profile of monocyte-derived
dendritic cells (MD-DCs) in HLA-B27+ axial spondyloarthritis (SpA) patients and healthy controls.
Methods: MD-DCs were differentiated with interleukin 4 (IL-4) and granulocyte-macrophage colony-stimulating factor
(GM-CSF) for seven days, starting from purified CD14+ monocytes and stimulated with lipopolysaccharide (LPS) for six
and twenty four hours. Their capacity to stimulate allogeneic CD4+ T cells from unrelated healthy donor was tested.
Transcriptomic study was performed with Affymetrix HuGene 1.0 ST microarrays. Gene expression levels were compared
between patients and controls using a multivariate design under a linear model (LIMMA). Real-time quantitative PCR
(qRT-PCR) was performed for validation of the most striking gene expression differences.
Results: The stimulatory capacity of allogeneic CD4+ T cells by MD-DCs from SpA patients was decreased. Transcriptomic
analysis revealed 81 genes differentially expressed in MD-DCs between SpA patients and controls (P <0.01 and
fold-change <0.66 or >1.5). Four selected genes were validated by qRT-PCR: ADAMTS15, CITED2, F13A1 and SELL.
Expression levels of ADAMTS15 and CITED2, encoding a metallopeptidase and a transcription factor, respectively,
were inversely correlated with each other (R = 0.75, P = 0.0003). Furthermore, in silico analysis identified several
genes of the Wnt signaling pathway having expression co-regulated with CITED2.
Conclusion: This study revealed altered function and gene expression pattern in MD-DCs from HLA-B27+ axial SpA.
Co-expression study showed an inverse correlation between ADAMTS15 and CITED2. Moreover, the Wnt signaling pathway
appeared as deregulated in SpA MD-DCs, a finding which may be connected to Th17-driven inflammatory responses.Introduction
Spondyloarthritis (SpA) is a chronic inflammatory
rheumatic disorder, with a prevalence of around 0.42%
in Caucasian populations [1]. Joint inflammation is re-
sponsible for pain and stiffness but long-term outcome
is mainly determined by new bone formation, which can
lead to complete ankylosis. Effective treatments such as* Correspondence: gilles.chiocchia@inserm.fr
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stated.TNF blockers can temporarily suppress inflammation,
but none has yet proven to affect long-term disease out-
come. Therefore, there is a need to better understand
pathological mechanisms controlling both initiation and
progression of SpA.
Genome-wide gene expression analysis is a powerful ap-
proach to identify molecular mechanisms responsible for
a disease. Microarray studies have already been conducted
in SpA, most of them focusing on the ankylosing spondyl-
itis (AS) subtype [2-7]. Each of those studies identified sev-
eral genes differentially expressed between patients andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Talpin et al. Arthritis Research & Therapy 2014, 16:417 Page 2 of 9
http://arthritis-research.com/content/16/4/417controls but there was very little overlap between their re-
sults, maybe due to the variety of protocols.
Several studies support an important role of dendritic
cells (DCs) in the pathogenesis of SpA. Indeed, aberrant
functions of DCs have been demonstrated in an HLA-
B27/human β2-microglobulin transgenic rat model of SpA
[8]. First, DCs from these rats have a decreased capacity to
stimulate primary allogeneic or syngeneic T cell responses
[9]. Furthermore, the proportion of conjugates formed be-
tween HLA-B27 DCs and naïve CD4+ T cells is reduced.
Moreover, mature HLA-B27 molecules expressed by DCs
appear to impair the formation of an antigen-independent
immunologic synapse with naïve CD4+ T cells by interfer-
ing with the engagement of co-stimulatory molecules [10].
Finally, B27 transgenic rat DCs were shown to favor
Th17 expansion [11,12] and to alter regulatory T cell
function, resulting in decreased IL-10 and enhanced IL-
17 production [13].
On this basis, we hypothesized that DCs also play an im-
portant role in human disease, as proposed in the HLA-
B27 transgenic rat model. The aim of the current study
was to compare functional capacity and the gene expres-
sion profile of monocyte-derived DCs (MD-DCs) in pa-
tients with HLA-B27+ axial SpA and healthy controls.
Methods
Patients and controls
We studied three different groups of patients and controls: 10
patients and 5 controls for monocyte subset characterization
by flow cytometry, 19 patients and 24 controls for mixed
lymphocyte reaction and 9 patients and 10 controls for the
MD-DC transcriptomic study (6 patients and 4 controls
were investigated for the two latter). All the patients were
HLA-B27+ and fulfilled the Assessment of SpondyloArthritis
International Society classification criteria for axial SpA [14].
Controls were healthy blood donors.
Patients’ and healthy controls’ characteristics are sum-
marized in the Additional files (see Additional file 1: Table
S1 and Additional file 2: Table S2, respectively). All partici-
pants in the study gave written informed consent and the
study was approved by local ethics committee of Ile-de-
France XI (Saint-Germaine-en-Laye France).Cell isolation, culture and stimulation
Peripheral blood mononuclear cells (PBMCs) were isolated
from 50 mL of blood by gradient separation on Ficoll
density gradient centrifugation (STEMCELL Technologies,
Grenoble, France). Monocytes used to generate MD-DCs
were purified by magnetic cell sorting using anti-CD14
monoclonal antibody (mAb)-coated beads (BD IMag, Le
Pont de Claix, France). Sorted monocytes were morpho-
logically homogeneous with 99% of CD14+ cells, as deter-
mined by flow cytometry.Monocytes were further cultured for 6 days in 24-well
plates (400,000 cells/500 μL) in Roswell Park Memorial
Institute (RPMI) 1640 medium supplemented with 10%
heat-inactivated fetal calf serum, 100 U/mL penicillin,
100 μg/mL streptomycin, 500 U/mL recombinant hu-
man granulocyte-macrophage colony stimulating factor
(rhGM-CSF) and 500 U/mL rhIL-4 (AbCys, Paris, France).
Then, the MD-DCs were stimulated or not with lipopoly-
saccharide (LPS) from Escherichia coli (LPS, Sigma-Aldrich,
St Louis, MO, USA) at a concentration of 100 ng/mL for
the last 6 or 24 hours of culture (further referred to as time
points H0, H6 and H24).
CD4+ T cells were purified from PBMCs from two un-
related healthy donors by magnetic cell sorting using
anti-CD4 monoclonal antibody (mAb)-coated beads (BD
IMag), and stored frozen until used for mixed lympho-
cyte reaction (MLR).
Flow cytometry
To characterize monocyte subsets, freshly purified PBMCs
were analyzed by six-color flow cytometry on FACS LSRII
apparatus. The gating strategy was based on a previous
report [15]. Monocytes were subdivided into three major
subsets: classical CD14++CD16−, intermediate CD14++
CD16+ and non-classical CD14+CD16++ monocytes. The
following anti-human mAbs were used: CD45-Amcyan (BD
Biosciences), HLA-DR-PerCP (BD Biosciences), CD19-ECD
(Beckman Coulter), CD14-QDot655 (Invitrogen), CD16-
APC-H7 (Beckman Coulter, Villepinte, France). The Live/
Dead blue Dye (Invitrogen) was used to exclude dead cells.
Samples of the purified monocytes used to generate
MD-DCs and of the resulting MD-DCs were routinely
stained with the following anti-human mAbs: CD14-FITC,
CD11c-APC, CD40-PE, HLA-I-FITC, HLA-DR-PerCP,
CD80-PE, CD83-APC and CD86-FITC (all from BD Bio-
science) and analyzed by flow cytometry on FACS canto II
apparatus (BD Biosciences).
Mixed lymphocyte reaction (MLR)
Purified allogeneic CD4+ T cells (105 cells per well) from
healthy donors were cultured with unstimulated (H0) or
LPS-stimulated (H6, H24) MD-DCs (104 cells per well),
in 96-well flat-bottomed culture dishes in a final volume of
200 μL. Proliferation of T cells was assayed by measuring
incorporation of 3H-deoxythymidine added (0.5 μCi per
well) after 6 days of culture, using a Microbeta scintillation
counter (Wallac, Turku, Finland). Data are expressed as the
mean counts per minute (CPM) in triplicate wells. An
MLR index (ratio of CPM of MLR on CPM of CD4+ T cells
only) was used to represent CD4+ T cell proliferation. Two
stored CD4+ T cell batches from different healthy donors
were sequentially used for MLR in two sets of experiments,
each including equivalent numbers of patient and control
MD-DC samples. As there was no statistically significant
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MD-DCs were disrupted and homogenized using RLT buf-
fer (Qiagen, Valencia, CA, USA). Total RNA was isolated
using RNeasy Mini Kit (Qiagen). RNA quantity and quality
were assessed using Agilent 2100 Bioanalyzer (Agilent,
Santa Clara, CA, USA). Only samples with an RNA integ-
rity number (RIN) above 8 were further processed.
Microarray hybridization
RNA was reverse-transcribed, converted to biotinylated
complementary RNA using standard Affymetrix protocol
(Affymetrix, Santa Clara, CA, USA) and hybridized to
the Affymetrix GeneChip Human Gene 1.0 ST Array by
the genomic platform of the Cochin Institute.
Differential gene expression validation by qRT-PCR
For validation, the relative gene expression levels of
candidate genes identified through the foregoing
microarray study were further quantified using qRT-PCR.
Briefly, RNA treated with DNase I (Invitrogen) was reverse-
transcribed using SuperscriptII (Invitrogen) and then quan-
tified using the SYBR green PCR Master Mix (Applied Bio-
systems) and the 7300 Real-Time PCR System (Applied
Biosystems). Primers were purchased from Eurofins MWG
(nucleotide sequences of the PCR primers are available in
Additional file 3: Table S3). The experiment design in-
cluded three technical replicates.Statistical analysis
Raw Affymetrix data (.cel files) from 57 arrays (correspond-
ing to H0, H6 and H24 time points of stimulation by LPS
for 19 subjects) were transformed by the Robust Multichip
Analysis (RMA) method using Bioconductor in R software
(library Affy) [16]. This transformation included back-
ground correction, normalization and summarization of ex-
pression values using Brainarray version 15 custom chip
definition (cdf) files generated with the Ensembl annotation
set [17]. Before analysis, genes were filtered on annotation
and expression level mean with a cut off at 6.11 (corre-
sponding to the mean of expression level of both anti-
genomic and intronic probes of housekeeping genes). Gene
expression levels were then fitted to a bivariate linear model
including disease status and time point after stimulation,
using the LInear Models for Microarray data (LIMMA)
package of Bioconductor in R environment to determine
differentially expressed genes [18]. The threshold for differ-
ential gene expression between patients and controls wasset to a global fold change above or below 1.5 with a nom-
inal P-value below 0.01.
For qRT-PCR validation, gene expression data were
computed with the ΔΔCq method, using three house-
keeping genes: RPL30, β-ACT and GAPDH. Then, two-
way analysis of variance (ANOVA) was used to test
differential gene expression among samples from SpA and
controls without (baseline; no treatment) and with LPS
treatment for 6 and 24 hours. In case of statistical signifi-
cance (P <0.05), post hoc t-tests with the Bonferroni cor-
rection allowed us to perform pairwise comparisons.
Paired genes co-expression study and molecular pathway
analysis
Pairwise correlations between gene expression levels were
tested using the nonparametric Spearman test. We used
the commercial software Genomatix Pathway System [19]
to identify significantly enriched pathways and functional
themes, among the list of the best correlated genes with
genes of interest.
Results
Functional impairment of MD-DCs from SpA patients
To verify that MD-DCs were differentiated from com-
parable monocyte populations between SpA patients and
controls, we analyzed monocytes subsets in both groups.
As shown in an additional file, the distribution of the
classical, intermediate and non-classical circulating sub-
sets among CD45+ PBMCs was similar in patients and
controls (see Additional file 4: Figure S1).
The cells obtained after 7 days of differentiation in cul-
ture in patients and controls were uniformly CD14−,
CD11c+, CD40+, HLA-DR+, CD83dim and CD86+, con-
sistent with a MD-DC phenotype. Moreover, HLA-DR,
CD80 and CD86 expression increased and CD83 was in-
duced on MD-DCs after LPS stimulation for 24 hours
(Additional file 5: Figure S2).
In the rat model of SpA, HLA-B27 transgenic DCs have
a decreased capacity to stimulate allogeneic T cells. Thus,
we tested the capacity of MD-DCs from HLA-B27+ SpA
patients to prime allogeneic CD4+ T cells using an in vitro
proliferation assay. A weaker proliferation of CD4+ T
cells was observed with SpA MD-DCs as compared to
controls, which was statistically significant before and
after 6 hours of LPS exposure (P <0.05 and P <0.01, re-
spectively; Figure 1).
Identification of differentially expressed genes in MD-DCs
between patients and controls
To investigate the mechanisms underlying the functional
defect of MD-DCs from SpA patients, we then compared
gene expression levels in those cells between SpA and
healthy donors upon stimulation with LPS. After filtering
on gene expression level and gene annotation, 13,021 genes
Figure 1 Impaired allogeneic T cell stimulatory capacity of
monocyte-derived dendritic cells (MD-DCs) from spondyloarthritis
(SpA) patients. MD-DCs from SpA patients and healthy controls that
were left unstimulated at baseline (H0), or were stimulated with
lipopolysaccharide (LPS) for 6 h or 24 h (H6 and H24, respectively) were
tested for their capacity to stimulate in vitro allogeneic CD4+ T cells.
Results are expressed as 3H-deoxythymidine incorporation after 6 days
of mixed lymphocyte reaction, in counts per minute (CPM) ratio. Bars
represent the mean proliferation index and standard error of the mean
induced by MD-DCs from 19 SpA patients and 24 healthy controls. The
Wilcoxon test showed significant differences at H0 (*P <0.05) and H6
(**P <0.01). MLR, mixed lymphocyte reaction.
Talpin et al. Arthritis Research & Therapy 2014, 16:417 Page 4 of 9
http://arthritis-research.com/content/16/4/417(57.3% of the genes present in the microarray) were kept
for further analysis. Expression data for MD-DCs either left
unstimulated or stimulated with LPS for 6 or 24 hours were
first globally compared between SpA patients and healthy
subjects. Unsupervised hierarchical clustering showed that
samples were perfectly grouped according to LPS stimula-
tion time points (Additional file 6: Figure S3) but not to the
disease status. Linear modeling nevertheless identified 81
genes differentially expressed between patients and controls
at any time point, with a nominal P-value <0.01 and a fold
change below 0.66 or greater than 1.5 (Additional file 7:Figure 2 Unsupervised hierarchical clustering of 57 samples based on
genes between spondyloarthritis (SpA) patients and controls. Each tim
Samples are clustered on the horizontal axis (top row: SpA patients, bottom ro
the degree of correlation between samples.Table S4). Of this set of genes, 61 were downregulated and
20 were upregulated in patients.
Using the extraction of the dataset corresponding to
these 81 genes, LPS stimulation time points were per-
fectly separated by unsupervised hierarchical clustering.
Furthermore, patients and controls were now clearly dis-
criminated, with only four misclassifications (one at H0,
two at H6 and one at H24) (Figure 2).
Four candidate genes were chosen for validation study
on the basis of their P-value, fold change and biological
relevance: ADAMTS15, CITED2, F13A1 and SELL. For
all four genes, the qRT-PCR data produced with the
RNA samples used for the microarray study confirmed
the significant differences in expression and the direc-
tion of changes between SpA patients and controls
(Table 1, Figure 3): ADAMTS15, F13A1 and SELL were
significantly upregulated in SpA samples, whereas CITED2
was downregulated.
Co-regulated genes in SpA patients
Examination of gene expression data indicated that some of
them displayed similarity in their expression profile, sug-
gesting co-regulation. Indeed, we found a highly significant
negative correlation between ADAMTS15 and CITED2 ex-
pression levels at H6 in both patient and control groups
(combined data: rho = −0.75; P = 0.0003; Figure 4).
Considering the transcriptional co-activator function of
CITED2 and its downregulation in SpA MD-DCs, we
sought whether genes other than ADAMTS15 shared a
similarly co-regulated expression pattern in patient MD-
DCs. We tested the correlation of the genome-wide ex-
pression matrix of patient MD-DCs with CITED2 expres-
sion in a pairwise fashion. A set of 222 genes was found
significantly correlated with CITED2 (P <0.01). They weremicroarray expression levels of the 81 differentially expressed
e point is color-coded (baseline (H0): blue, 6 h (H6): red, 24 h (H24): green).
w: healthy controls), with the length on the vertical axis representing
Table 1 qRT-PCR expression analysis of four selected genes
in monocyte-derived dendritic cells from spondyloarthritis
patients, as compared to controls
Gene Microarray qRT-PCR
P-value P-value Fold change
Disease Disease/time H0 H6 H24
ADAMTS15 0.0003 0.0005 0.04 2.2 5.63 2.2
CITED2 0.0007 0.21 0.031 0.94 0.51 0.99
F13A1 0.00006 0.019 0.001 1.32 1.25 5.05
SELL 0.006 0.012 0.8 3.57 3.47 2.97
P-value is reported considering the global effect, the effect of the disease
status only or the effect of the disease status adjusted for time. Bold text
indicates significant P-values and at what time the modulation of gene
expression was significantly different between patients and controls.
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terrogate their biological relevance. This revealed a signifi-
cant enrichment of genes belonging to the Wnt signaling
pathway (P = 2.48 × 10-4) in the SpA group. In the con-
trols, there was no significant correlation between expres-
sion levels of CITED2 and the four genes identified in the
Wnt pathway (that is, WNT1, WNT10B, FZD4 and ROR2)
(Figure 5). This co-regulation pattern involving four genes
of the Wnt signaling pathway was therefore specifically as-
sociated with the disease.Figure 3 Scatter plots showing qRT-PCR expression levels in spondylo
(A), CITED2 (B), F13A1 (C) and SELL (D). The x-axis of the plots represents
(H0), 6 h (H6) and 24 h (H24)) and the y-axis shows the log2 of gene expre
***P <0.0005, for SpA versus controls.Discussion
Starting from the hypothesis that aberrant DCs function
could play a critical role in the development of SpA,
we showed here for the first time that the capacity of
MD-DCs to stimulate allogeneic CD4+ T cell response
was impaired in SpA patients compared to controls. The
genome-wide transcriptome of these MD-DCs elicited by
LPS stimulation revealed 81 genes differentially expressed,
4 of which have been validated by RT-qPCR. Finally, we
identified the Wnt signaling pathway as dysregulated in
patients.
Our choice to study in vitro-differentiated DCs rather
than DCs purified from peripheral blood had the advan-
tage to remove those cells from in vivo influences, such as
non-specific acute inflammation and drug therapy. There-
fore, the differences that we observed between DCs from
SpA and controls were more likely to be intrinsic to the
DC and could be involved in the disease mechanism.
First, we demonstrated that MD-DCs differentiated
from similar monocyte populations in both groups. Then,
we observed that the ability of SpA MD-DCs to stimulate
allogeneic CD4+ T cell proliferation was markedly defect-
ive, as compared to controls, as previously shown in SpA-
prone HLA-B27 transgenic rats. The molecular basis for
this impaired DC function has yet to be elucidated.arthritis (SpA) and controls of the 4 selected genes: ADAMTS15
the three lipopolysaccharide-stimulation time points (baseline
ssion level normalized with housekeeping genes (ΔΔCt). *P <0.05,
Figure 4 Correlation of qRT-PCR expression levels between
CITED2 and ADAMTS15. Expression is shown for H6 time-point in
mixed spondyloarthritis (open circles) and control (black triangles)
samples. P-value (P) and nonparametric Spearman correlation
coefficient value (rho) are shown.
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time-dependent global transcriptome of MD-DCs in re-
sponse to LPS stimulation. A number of microarray-based
studies have previously been undertaken in AS, on whole
blood cells [3-5], PBMCs [6,7] or macrophages [2]. How-
ever, no transcriptomic analysis had been conducted on
DCs. Of note, as we worked on a homogeneous cell popu-
lation rather than on cell mixture, our results were not
confounded by variations in the composition of the cell
populations [20]. The time-dependency of our gene profil-
ing is also a novel aspect, rarely investigated in humans.
Our analysis revealed 81 genes differentially expressed
in resting and/or LPS-stimulated MD-DCs between SpA
patients and controls. Of note, we did not identify a
reverse interferon signature, such as in HLA-B27 trans-
genic rat splenic DCs [21] or in SpA patients monocyte-
derived macrophages [2]. Such a discrepancy could be
explained by differences in culture conditions. Here, we
used IL-4 to differentiate MD-DCs, a cytokine that op-
poses interferon and interferon-induced gene expressionFigure 5 Co-expression of the Wnt signaling pathway with CITED2 in
identified by studying genes co-expressed at 6 h (H6) with CITED2 in the w
and color code (scale on the right side) indicate nonparametric Spearmanand this might have blunted interferon-related differences
between groups. Based on the magnitude of their variation
between patients and controls, the level of statistical sig-
nificance, and their biological relevance, we selected four
of these genes that we validated using qRT-PCR.
We found an increased expression of ADAMTS15 (A
Disintegrin And Metalloproteinase with ThromboSpon-
din motif) in SpA. Although the ADAMTS family has not
yet been implicated in this disorder, numerous studies have
identified a role for metalloproteinases (MMPs) in SpA sus-
ceptibility and severity [22-24]. Of note, ADAMTS15 was
shown to be expressed in the joint with decreased expres-
sion in osteoarthritis [25]. Thus, ADAMTS15 could be im-
plicated in the cartilage and/or bone turnover that takes
place during joint inflammation, such as in SpA.
CITED2 functions as a context-dependent transcrip-
tional modulator to up- or downregulate the expression of
specific genes [26-28]. Here, the expression of CITED2
was downregulated in SpA MD-DCs. We further showed
an inverse correlation between CITED2 and ADAMTS15
expression after 6 hours of LPS treatment. Interestingly,
similar inverse correlation has previously been reported be-
tween CITED2 and several MMP family members [29,30].
MMPs constitute a very important group of proteolytic en-
zymes in joint tissues. Thus, it has been suggested that
CITED2 exerted chondroprotective effects through MMP
downregulation [31]. The downregulation of CITED2 and
the inverse correlation between CITED2 and ADAMTS15
expression that we observed here suggest that DCs or other
phagocytic mononuclear cells, such as macrophages and
osteoclasts, could be implicated in SpA joint resorption
through heightened metallopeptidase activity.
In silico pathway analysis conducted on CITED2 co-
expressed genes highlighted downregulation of several fac-
tors belonging to the canonical (that is, WNT1, WNT10B
and FRZL4) and non-canonical (ROR2) Wnt signaling
pathways, of potential relevance for SpA pathogenesis.
First, factors of the canonical Wnt pathway were shown to
play a crucial role either in bone formation or destruction
in inflammatory arthritis [32,33], such as WNT10bspondyloarthritis (SpA). Graphical view of the Wnt pathway
hole microarray dataset in patients (A) and in controls (B). Numbers
correlation coefficient of the network's gene with CITED2.
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β-catenin signaling in DCs was shown to concur to
regulatory T cell differentiation and conversely to in-
hibit Th17 differentiation [36]. Moreover, ROR2 is a sig-
naling component of the non-canonical Wnt pathway
acting on actin cytoskeleton to stimulate cell migration
[37,38]. Interestingly, altered T cell stimulation was
linked to defective cytoskeleton dynamics in HLA-B27
transgenic rat DCs [39].
F13A1 encodes the coagulation factor XIII A subunit,
a transglutaminase enzyme. It has multiple extra- and
intracellular functions, including a role in cartilage and
bone development. Hence, increased factor XIII A ex-
pression has previously been associated with cartilage
ageing and degenerescence [40]. Fibrin crosslinking
by factor XIII is of crucial importance not only for
hemostasis, but also for inflammation. For instance,
factor XIII A-subunit genotype was shown to influence
C-reactive protein levels during inflammation in
rheumatoid arthritis (RA) [41].
Finally, SELL encodes the lymphocyte homing recep-
tor L-selectin/CD62L, one of the major adhesion mole-
cules, which regulates entry of neutrophils and monocytes
into inflamed tissues and contributes to the severity of
joint inflammation in experimental arthritis [42]. Thus,
upregulation of SELL, as shown here in DCs could well
participate in joint inflammation in SpA. Interestingly, this
gene was also found to be upregulated in splenic DCs
from the HLA-B27/human β2-microglobulin transgenic
rat [21].
Conclusions
Results of the present study reveal the defective func-
tional capacity of DCs from SpA patients, as compared
to controls. Furthermore, our results demonstrate sig-
nificant changes in MD-DCs gene expression upon
LPS stimulation that may be inherent to SpA patients.
Some of them (that is, decreased Wnt signaling) could
account for the altered DC function that provided a ra-
tionale for the present study. Others (that is, upregula-
tion of ADAMTS15, F13A1 and SELL) would concur to
reinforce tissue inflammation and/or damage. Finally, the
co-expression of CITED2 co-transcriptional factor with
several of the foregoing genes (that is, the Wnt signaling
pathway and ADAMTS15) supports the hypothesis that a
coordinated deregulation taking place in DCs may play an
important role in SpA pathogenesis.Additional files
Additional file 1: Table S1. Characteristics of the study patients.*SpA,
spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity
Index; NSAID, non-steroidal anti-inflammatory drug; TNF, tumor necrosis
factor. ND, not done. *The registered manifestations correspond to thosepresent at the time of examination, or retrieved from past-medical
history. **Refers to radiographic sacroiliitis ≥ grade II bilateral or grade III
unilateral. ***Six patients are common to both studies. ****Data available
for nine patients.
Additional file 2: Table S2. Characteristics of the study healthy controls.
Additional file 3: Table S3. Nucleotide sequence of the PCR primers.
Additional file 4: Figure S1. Comparison of monocyte subsets
distribution among peripheral blood mononuclear cells (PBMCs) between
spondyloarthritis (SpA) patients and healthy controls (Ctrl) by six-color
flow cytometry. Distribution of monocyte subsets among CD45+ PBMC
was studied in five healthy donors (clear boxes) and 10 HLA-B27+ SpA
patients (gray boxes). Results are represented as boxes, bars indicate
medians. The mean age of healthy donors was 42 years at the time of
the study and 40% of them were men. Characteristics of the patients are
shown in Additional file 1: Table S1.
Additional file 5: Figure S2. Phenotypic characterization of purified
monocytes and monocyte-derived dendritic cells (MD-DCs) by flow
cytometry. Results of one healthy donor representative of study subjects
are shown. Monocytes (D0) were CD14+, CD11c+, CD40−, HLA-I+, HLA-
DR+, CD80−, CD83− and CD86−. MD-DCs (D7) were CD14−, CD11c+,
CD40+, HLA-I+, HLA-DR+, CD80−, CD83dim, and CD86+. HLA-DR, CD83
and CD86 expression increased, and CD80 was induced on MD-DCs
after lipolpolysaccharide (LPS) stimulation for 24 h (H24). Clear plot
represents control isotype and gray plot the tested antibody.
Additional file 6: Figure S3. Unsupervised hierarchical clustering of 57
samples based on whole-genome gene expression levels. Each time point is
represented by a color (baseline (H0): blue, 6 h (H6): red, 24 h (H24): green).
Samples are clustered on the horizontal axis (top row: spondyloarthritis
(SpA) patients, bottom row: healthy controls).
Additional file 7: Table S4. List of the genes differentially expressed in
monocyte-derived dendritic cells (MD-DCs) between spondyloarthritis
(SpA) and controls, ranked by fold change.**The criteria for the inclusion
of genes in this table are described in Patients and Methods. Global
values are LInear models for microarray data (LIMMA) values. The four
genes selected for qRT-PCR validation are in bold text.
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